Background/Aim: Recurrent vulvovaginal candidosis (RVVC) needs alternative therapeutic approaches. Gentian violet (GeV) has been traditionally used to treat mucocutaneous candidosis. The aim of the present study was to evaluate the in vitro activity of GeV against Candida spp. and contribute to clarify the mechanism of action, supporting its clinical therapeutic use. Methods: Seventeen clinical Candida isolates from RVVC and one C. albicans type collection (ATCC 10231) were studied; the antifungal activity of GeV was evaluated according to the CLSI M27-A3 protocol. To elucidate its mechanism of action, cells were stained with propidium iodide and afterwards analyzed by flow cytometer. Results: GeV showed a fungicidal activity against most Candida spp. C. albicans and C. tropicalis were the most susceptible species. Minimal lethal concentrations were similar to minimal inhibitory concentrations for most tested strains. The fungicidal effect was not related to a primary lesion of the cytoplasmic membrane. Conclusion: In accordance with our findings, GeV is a valuable potent fungicidal drug to be used topically, isolated or in combination with oral antifungal drugs, particularly in RVVC cases.

Keywords:
Gentian violet, Antibiotherapy, Candida, Vulvovaginal candidosis
1.
Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, Reed BD, Summers PR: Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998;178:203–211.
2.
Mardh PA, Rodrigues AG, Genc M, Novikova N, Martinez-de-Oliveira J, Guaschino S: Facts and myths on recurrent vulvovaginal candidosis – a review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy. Int J STD AIDS 2002;13:522–539.
3.
Workowski KA, Berman SM: Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006;55:1–94.
4.
Sobel JD: Limitations of antifungal agents in the treatment of Candida vaginitis: future challenges. Drug Resist Updat 1999;2:148–152.
5.
Spinillo A, Capuzzo E, Gulminetti R, Marone P, Colonna L, Piazzi G: Prevalence of and risk factors for fungal vaginitis caused by non-albicans species. Am J Obstet Gynecol 1997;176:138–141.
6.
Fidel PL, Vazquez JA, Sobel JD: Candida glabrata: an important fungal pathogen for the 21st century. Clin Microbiol Newslett 2001;23.
7.
Rogers TR: Antifungal drug resistance: does it matter? Int J Infect Dis 2002;6(suppl 1):S47–S53.
8.
Rogers TR: Antifungal drug resistance: limited data, dramatic impact? Int J Antimicrob Agents 2006;27(suppl 1):7–11.
9.
Donders G, Bellen G, Byttebier G, Verguts L, Hinoul P, Walckiers R, Stalpaert M, Vereecken A, Van Eldere J: Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). Am J Obstet Gynecol 2008;199:613 e1–9.
10.
Shahid Z, Sobel JD: Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy. Diagn Microbiol Infect Dis 2009;64:354–356.
11.
Das Neves J, Pinto E, Teixeira B, Dias G, Rocha P, Cunha T, Santos B, Amaral M H, Bahia MF: Local treatment of vulvovaginal candidosis: general and practical considerations. Drugs 2008;68:1787–802.
12.
Palmeira-de-Oliveira A, Salgueiro L, Palmeira-de-Oliveira R, Martinez-de-Oliveira J, Pina-Vaz C, Queiroz JA, Rodrigues AG: Anti-Candida activity of essential oils. Mini Rev Med Chem 2009;9:1292–1305.
13.
Lima O, Oliveira RAG, Lima EO, Farias NMP, Souza EL: Atividade antifúngica de óleos essenciais sobre espécies de Candida. Rev Bras Farmacogn 2006;16:197–201.
14.
Palmeira-de-Oliveira A, Ribeiro MP, Palmeira-de-Oliveira R, Gaspar C, Costa-de-Oliveira S, Correia IJ, Pina-Vaz C, Martinez Oliveira J, Queiroz JA, Rodrigues AG: Anti-Candida activity of a chitosan hydrogel: mechanism of action and cytotoxicity profile. Gynecol Obstet Invest 2010;70:322–327.
15.
Pinto E, Pina-Vaz C, Salgueiro L, Goncalves MJ, Costa-de-Oliveira S, Cavaleiro C, Palmeira A, Rodrigues A, Martinez-de-Oliveira J: Antifungal activity of the essential oil of Thymus pulegioides on Candida, Aspergillus and dermatophyte species. J Med Microbiol 2006;55:1367–1373.
16.
Das Neves J, Pinto E, Amaral M, Bahia M: Antifungal activity of a gel containing Thymus vulgaris essential oil against Candida species commonly involved in vulvovaginal candidosis. Pharm Biol 2009;47:151–153.
17.
White DJ, Johnson EM, Warnock DW: Management of persistent vulvovaginal candidosis due to azole-resistant Candida glabrata. Genitourin Med 1993;69:112–114.
18.
Urdaneta E, Benaim Pinto V, Gavaller B: Candidiasis. Mycopathologia 1961;15:317–342.
19.
Traboulsi RS, Mukherjee PK, Ghannoum MA: In vitro activity of inexpensive topical alternatives against Candida spp. isolated from the oral cavity of HIV-infected patients. Int J Antimicrob Agents 2008;31:272–276.
20.
Ying S, Qing S, Chunyang L: The effect of gentian violet on virulent properties of Candida albicans. Mycopathologia 2010;169:279–285.
21.
CETEMED-ANF: Formulário Galénico Português. Lisboa, Centro Tecnológico do Medicamento and Associação Nacional de Farmácias, 2005, vol 1, p 5.
22.
CLSI: Reference method for broth dilution antifungal susceptibility testing of yeast; approved standard, ed 3; in CLSI Document M27-A3. Wayne/PA, Clinical and Laboratory Standard Institute, 2008.
23.
Canton E, Peman J, Viudes A, Quindos G, Gobernado M, Espinel-Ingroff A: Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagn Microbiol Infect Dis 2003;45:203–206.
24.
Pina-Vaz C, Rodrigues AG: Evaluation of antifungal susceptibility using flow cytometry. Methods Mol Biol 2010;638:281–289.
25.
Rosenkranz HS, Carr HS: Possible hazard in use of gentian violet. Br Med J 1971;iii:702–703.
26.
Wolfe AD: Influence of cationic triphenylmethane dyes upon DNA polymerization and product hydrolysis by Escherichia coli polymerase I. Biochemistry 1977;16:30–33.
27.
Harrelson WG Jr, Mason RP: Microsomal reduction of gentian violet. Evidence for cytochrome P450-catalyzed free radical formation. Mol Pharmacol 1982;22:239–242.
28.
Littlefield NA, Blackwell BN, Hewitt CC, Gaylor DW: Chronic toxicity and carcinogenicity studies of gentian violet in mice. Fundam Appl Toxicol 1985;5:902–912.
29.
Tolba MK, Saleh AM: Studies on the mechanism of fungicidal action of crystal violet on mycelial felts of Fusarium culmorum. Arch Mikrobiol 1963;47:201–206.
30.
Shrand H: Thrush in the newborn. Br Med J 1961;ii:1530–1533.
31.
Donders GG, Bellen G, Mendling W: Management of recurrent vulvo-vaginal candidosis as a chronic illness. Gynecol Obstet Invest 2010;70:306–321.
32.
Wright SC, Maree JE, Sibanyoni M: Treatment of oral thrush in HIV/AIDS patients with lemon juice and lemon grass (Cymbopogon citratus) and gentian violet. Phytomedicine 2009;16:118–124.
33.
Horsfield P, Logan FA, Newey JA: Letter: Oral irritation with gentian violet. Br Med J 1976;ii:529.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.